Skip links
OncoOne

Publication: Drug Target Review Issue 3 – Features our CEO

Our thanks to Drug Target Review for featuring an article by our CEO and Co-Founder, Randolf Kerschbaumer, highlighting novel capabilities that address elusive therapeutic targets and their impact on the treatment paradigm for patients living with cancer. Download the article here to learn more about

Publication: We published our first article on ON104 – the bioengineered second generation anti-oxMIF antibody for chronic inflammatory diseases.

Thrilled to share a significant milestone: Our pioneering research paper on targeting oxidized macrophage migration inhibitory factor (oxMIF) to treat chronic inflammatory diseases, “The Newly Engineered Monoclonal Antibody ON104, Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF), Ameliorates Clinical and Histopathological Signs of Collagen-Induced Arthritis,” is

OncoOne Celebrates its 5th Anniversary.

It is hard to believe how time flies, and that OncoOne already celebrated its 5th anniversary last month. Together with our team, we took this opportunity to commemorate this amazing accomplishment. In just 5 years, we have raised €18M in funding from private investors and

60TH ERA Congress, June 15-18, 2023, Milan, IT

We are proud to announce that Christine Landlinger-Schubert, our VP of Preclinical and Translational R&D, will be delivering a Focused Oral presentation at the ERA Congress held from June 15-18 in Milan, Italy. Christine’s presentation titled “ON104: A novel bioengineered antibody targeting oxidized Macrophage Migration

BIO International Convention, June 5-8, 2023, Boston, MA, US

OncoOne’s CEO, Randolf Kerschbaumer, will be attending the BIO International Convention in Boston from June 5-8! With a projected 44,000+ meetings scheduled over four days, we can’t wait to connect with like-minded companies who share our passion for science.

PEGS 2023 Boston, May 15-19, 2023, Boston, MA, US

Join our CTO Alexander Schinagl at PEGS Boston. OncoOne is excited to present our latest research on “Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer” at PEGS23. The study highlights the potential of our innovative PreTarg-it® platform combining a bispecific

Bio€quity 2023, May 14-16, 2023, Dublin, IR

OncoOne’s CSO, Michael Thiele, will be attending #BIOEQUITY in Dublin from May 14-16! This is a great opportunity to connect with us and discuss potential collaborations to advance our innovative research in oncology and inflammation therapies to the clinic.